13 results
6-K
EX-99.2
IFRX
InflaRx N.V.
10 Aug 23
Report of Foreign Private Issuer
8:00am
the EUA, we may be able to generate limited revenues through sales of Gohibic (vilobelimab) to U.S. hospitals under the EUA.
For this, we are hiring
6-K
EX-99.2
IFRX
InflaRx N.V.
11 May 23
Current report (foreign)
8:00am
in The Lancet Respiratory Medicine in September 2022.
II-1
We are preparing for the commercialization of Gohibic (vilobelimab). For this, we are hiring … (vilobelimab) in the future.
For this, we are hiring experts with relevant experience in the commercialization of medical products and are building
6-K
r3hbkzf9fgfn8pe
24 Feb 21
Current report (foreign)
4:16pm
6-K
EX-99.3
9px x0bguslh
23 May 19
Current report (foreign)
8:00am
20-F/A
jptgacbj6g
29 Mar 19
Annual report (foreign) (amended)
4:23pm
424B4
yr2m 273jhla39rt
7 May 18
Prospectus supplement with pricing info
4:47pm
F-1
uv39vxbb 18
2 May 18
Registration statement (foreign)
7:10am
20-F
mgqh4yaa4ybsfyec
29 Mar 18
Annual report (foreign)
12:00am
- Prev
- 1
- Next